Morgan Stanley (NYSE:MS) analyst Ricky Goldwasser maintained a Hold rating on Quest Diagnostics (NYSE:DGX) Inc on Tuesday, setting a price target of $165, which is approximately 9.44% above the present share price of $150.77.
Goldwasser expects Quest Diagnostics Inc to post earnings per share (EPS) of $5.05 for the third quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Moderate Buy rating of shares in Quest Diagnostics, with an average price target of $158.71.
The analysts price targets range from a high of $166 to a low of $148.
In its latest earnings report, released on 06/30/2021, the company reported a quarterly revenue of $2.55 billion and a net profit of $533 million. The company's market cap is $18.42 billion.
According to TipRanks.com, Morgan Stanley analyst Ricky Goldwasser is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 18.8% and a 67.48% success rate.
Quest Diagnostics, Inc. engages in the provision fo diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.